There is compelling evidence that the use of certain beta-blockers and an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) can alleviate symptoms, reduce hospitalisations and extend the survival of patients with CHF [5, 6]. The gene discussed is ACE; the disease is congestive heart failure.